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Introduction
Prostate cancer is the second most frequently diagnosed 
cancer in men and the fifth most common cancer overall 
worldwide (Globocan 2008). Advancing age, race, geo-
graphical distribution, diet and family history are the 
important risk factors contributing to the incidence of this 
disease (Isaacs et al. 2002). Prostate cancer is mainly a 
disease of ageing as most cases occur above the age of 60, 
indicating a slow development of the disease over the years 
(Khandrika et al. 2009). Men with non-clinical defined 
prostate cancer at the age of 80 or 90 would be likely to 
die of other causes rather than the disease itself (Lin and 
Nelson 2003). Therefore, a strategy of chemoprevention 
to prevent or delay development of the disease in younger 
men would be useful and could reduce the prevalence of 
clinically manifest prostate cancer. LNCaP is an androgen-
dependent prostate carcinoma cell line that is considered to 
represent early stage of prostate cancer development and 
mimics the disease progression (Dozmorov et al. 2009). 
Thus, this cell line model is more representative than the 
other prostate cancer cell lines such as PC-3 and DU-145 to 
study the effect of aspirin in cancer chemoprevention.
Aspirin use is known to be associated with the chemo-
prevention of colorectal cancer. However, there is a lack of 
convincing clinical association between aspirin use and a 
reduction of prostate cancer incidence, although some stud-
ies imply that aspirin use might be inversely related to the 
risks of developing prostate cancer (Mahmud et al. 2004; 
Rothwell et al. 2011; Bosetti et al. 2009). In vitro studies 
reported that NSAIDs could inhibit proliferation of prostate 
cancer cells such that a selective COX-2 inhibitor, NS398 
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or celecoxib, and can result in apoptosis (Liu et al. 1998; 
Hsu et al. 2000). The underlying mechanisms are thought 
to be related to the inhibition of cyclooxygenases (COX-1 
and -2) and decreased production of prostaglandins 
(Michael et al. 2012). However, it has been suggested that 
mechanisms that are not dependent on COX inhibition such 
as inhibition of NF-κB (Babbar et al. 2006) and induction 
of polyamine catabolism (Hughes et al. 2012) may also be 
involved in this process.
Polyamines (putrescine, spermidine and spermine) are 
small polycations present in all mammalian cells. They are 
indispensable growth factors stimulating cell proliferation 
through binding to DNA, RNA and proteins (Wallace 2000; 
Wallace et al. 2003; Criss 2003). This has made the poly-
amine pathway an attractive target for growth inhibition 
and for the development of potential novel anticancer strat-
egies. Spermidine/spermine N1-acetyltransferase (SSAT) 
is the first enzyme in polyamine catabolism. It acetylates 
spermidine and spermine to form N1-acetylspermidine and 
N1-acetylspermine, respectively. Acetylation by SSAT is a 
prerequisite for the export of intracellular polyamines when 
excess polyamines are present (Shappell et al. 1993). The 
majority of N1-acetylated polyamines produced by SSAT 
are exported out of the cell via the polyamine export sys-
tem, thus maintaining intracellular polyamine concentra-
tions within predefined limits to maintain optimal rates of 
cell growth (Pegg 2009).
The SSAT gene is highly inducible by many stimuli 
including cell stress, toxins, anticancer drugs and poly-
amine analogues, e.g., N1,N11-diethylnorspermine (Man-
dal et al. 2013). An increase in SSAT activity can lead to 
an inhibition of cell growth in a number of tumour cell 
lines (Mandal et al. 2013; Vujcic et al. 2000; Kramer et al. 
2008). This is mainly thought to be as a result of a disrup-
tion to the cellular polyamine metabolism. Aspirin, as a 
growth inhibitor in cancer cells, is recognised as an inducer 
of SSAT, which is associated with the binding of NF-κB on 
the Sat1 gene (Babbar et al. 2006).
The aim of this study was to investigate whether there 
is an association between SSAT activity, the subsequently 
altered polyamine metabolism and the sensitivity of 
prostate cancer cells to aspirin. Our hypothesis was that 
increased SSAT activity will enhance the growth inhibitory 
effects of the drugs.
Materials and methods
Chemicals and labware
Aspirin, acetyl-coenzyme A, aminoguanidine hemi-sul-
phate, bovine serum albumin, tetracycline hydrochloride, 
trypan blue, dansyl chloride, 3-(4,5-dimethylthiazolyl)-
2,5-diphenyl-tetrazolium bromide (MTT) and 1,7-diamino-
heptane were purchased from Sigma-Aldrich, Co. (Poole, 
UK). Copper sulphate and toluene were purchased from 
Sigma-Aldrich, Co. (Gillingham, UK). Folin’s-Ciocalteau 
reagent was purchased from BDH Chemical Co. (Poole, 
UK). Dithiothreitol was purchased from Sigma Chemi-
cal Co. (St. Louis, USA). Geneticin (G418) hygromycin 
B, RPMI1640 medium, trypsin, 60 mm diameter cell cul-
ture dishes and T75 cm2 cell culture flasks were purchased 
from PAA Laboratories Ltd. (Yeovil, UK). Perchloric acid 
and methanol were purchased from VWR International 
Ltd. (Lutterworth, UK). Potassium sodium tartrate was 
purchased from Sigma-Aldrich Co. (Spain). Scintillation 
cocktail was purchased from GE Healthcare (Buckingham-
shire, UK). Tris base was purchased from Melford Labo-
ratories Ltd. (Ipswich, UK). Acetone was purchased from 
Fisher Scientific Ltd. (Loughborough, UK). l-Proline was 
purchased from Sigma-Aldrich Co. (China). N1-Acetyl-
spermidine hydrochloride and N1-acetylspermine trihydro-
chloride were purchased from Fluka (Switzerland). Sodium 
carbonate decahydrate was purchased from Sigma-Aldrich, 
Co. (Germany). Foetal bovine serum (tetracycline free) was 
purchased from Labtech International Ltd. (Uckfield, UK). 
[3H] acetyl-coenzyme A and [14C] l-ornithine were pur-
chased from PerkinElmer (Cambridge, UK).
Cell culture
The SSAT human cDNA transfected LNCaP cell line 
was a kind gift from Drs Carl Porter and Debora Kramer 
(Roswell Park Memorial Institute, Buffalo, USA). This cell 
line was genetically transfected with SSAT human cDNA 
using the tetracycline-off (Tet-off) Advanced Inducible 
Gene Expression System. Cells were cultured routinely in 
the presence of tetracycline (Tet) that inhibited the exog-
enous SSAT expression, producing basal SSAT enzymatic 
activity (2.13 ± 0.51 pmol/min/mg protein) represented 
as SSAT− cells. In the absence of Tet, the SAT1 gene 
transcription was overexpressed leading to a significant 
increase in SSAT enzymatic activity (52.38 ± 3.88 pmol/
min/mg protein) represented as SSAT+ cells. Culture 
medium: RPMI1640 with l-glutamine + 50 mg/ml 
G418 + 150 µg/ml hygromycin B + 1 mM aminoguani-
dine + 10 % (v/v) Tet free Foetal Bovine Serum + 0.4 µg/
ml Tet (Tet-free culture medium was the same but with-
out Tet supplementation). The medium was replaced every 
two days due to a short half-life of Tet in culture (<48 h). 
LNCap cell seeding density was 2.4 × 104/cm2. The cells 
were cultured routinely in a T75 cm2 culture flask contain-
ing 15 ml culture medium at 37 °C in a humidified incuba-
tor supplemented with 5 % CO2.
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Trypan blue cell exclusion assay
The cells were plated in a 60 mm diameter cell culture dish 
in duplicate and incubated for 48 h prior to treatment with 
aspirin (2 M stock in ethanol). The cells were trypsinized 
and stained with trypan blue, and viable cell numbers were 
counted under a Zeiss light microscope.
SSAT enzyme activity assay
The method of measuring SSAT activity was described 
by Wallace and Evans (1998). Cells were lysed in 0.5 ml 
hypotonic lysis buffer [10 mM Tris (pH 7.2 at 4 °C), 
1 mM EDTA and 2.5 mM dithiothreitol]. 40 µl of the cell 
lysate was used for protein quantification (Lowry assay). 
The remaining cell homogenate was ultra-centrifuged at 
100,000 gav for 70 min at 4 °C to separate cytosol. 60 μl 
of the cytosol was assayed in duplicate in addition of 10 μl 
of 30 mM spermidine and 10 μl of 1 M Tris HCl (pH 7.8 
at 37 °C), and incubated at 37 °C for 2 min. The reaction 
was started in ten second cycles on the addition of 10 μl of 
250 μM acetyl CoA and 10 μl of 0.33 µCi of [3H]-acetyl 
CoA. All the samples were incubated for 10 min at 37 °C, 
and then 20 μl of 1 M hydroxylamine was assayed stop the 
reaction. Samples were boiled for 3 min to precipitate any 
remaining protein, and centrifuged at 1600g for 3 min to 
pellet the protein. 30 μl of the supernatant was spotted in 
duplicate onto a Whatman P81 cellulose phosphate-loaded 
disc. The discs were dried and washed once in tap water, 
three times in distilled water for 2 min, and finally once in 
100 % ethanol to remove unbound [3H]-acetyl CoA. The 
discs were dried again. Each dried paper disc was trans-
ferred into a scintillation vial with an addition of 4 ml 
biodegradable scintillation fluid. The radioactivity of the 
samples was determined via a tritium protocol by using a 
Packard 1900 CA Tris carb scintillation analyser. Results 
were shown as pmol N1-acetylspermidine formed/min/mg 
protein.
ODC enzyme activity assay
ODC activity can be determined by measuring the amount 
of radiolabelled carbon dioxide ([14]CO2) produced during 
the decarboxylation of l-[l-14C] ornithine to form putres-
cine (Tabib 1998). The reaction was carried out in a sealed 
glass tube and CO2 was trapped in benzethonium hydrox-
ide solution. The cell pellet was lysed in 0.5 ml homog-
enising buffer (10 mM Tris–HCl, 2.5 mM dithiothreitol 
and 0.1 mM EDTA). 40 µl of the homogenate was taken 
for protein content determination (Lowry assay). The cell 
homogenate was centrifuged at a speed of 35,000g at 4 °C 
for 30 min. A stock assay mixes in which 50 µl aliquot 
was dispensed into each reaction tube. The mixture was 
composed of 12.5 µl of 1 M Tris–HCl (pH 7.5 at 37 °C), 
5 µl of 2 mM pyridoxal 5′-phosphate, 2.5 µl of 250 mM 
dithiothreitol, 5 µl of 20 mM l-ornithine, and 2.5 µl of l-[l-
14C] ornithine, and 22.5 µl of deionised water. To each pre-
chilled tube, 100 µl of the homogenising buffer and 50 µl 
aliquot of the assay mixture stock were added. 100 µl ben-
zethonium hydroxide was placed in each well which had 
been inserted into the rubber stopper for absorbing released 
[14]CO2. Finally, 100 µl of the enzyme extract was added to 
the reaction tube, making a final volume of 250 µl. 100 µl 
of the homogenising buffer instead of the enzyme extract 
was used as the blanks. All tubes were sealed tightly with 
the rubber stoppers with inserted wells and incubated in a 
shaking water bath for 1 h at 37 °C. 0.3 ml of 2 M perchlo-
ric acid was assayed per tube to stop the reaction and the 
tubes were further incubated for 45 min. All the wells from 
the tubes were transferred into scintillation vials in addition 
of 4 ml scintillation fluid. The vials were left in dark over-
night. Each sample was counted as disintegrations per min-
ute (dpm) for 10 min using a [14C] protocol by a Canberra 
Packard 1900A liquid scintillation analyser. Results were 
calculated as pmol 14CO2 generated/h/mg protein.
Measurement of intracellular polyamine content 
by LC–MS–MS
Perchloric acid-extracted intracellular polyamines were 
quantified using a Thermo Surveyor-TSQ Quantum sys-
tem (Thermo Scientific, Hemel Hempstead, UK) follow-
ing derivatization with dansyl chloride in a total run time 
of 6 min. The derivatised polyamines were resolved using 
a 5 µl Hichrom HIRPB column (150 × 2.1 mm) and guard 
cartridge (Hichrom Ltd. Reading, UK) with a mobile phase 
consisting of water/methanol/formic acid (10/90/0.02). The 
flow rate was 200 µl/min, the column was maintained at 
40 °C and the autosampler at 4 °C with 2 µl injected onto the 
chromatograph. The column eluent was diverted to waste for 
the first 2 min of the run. The TSQ Quantum was equipped 
with an electrospray (ESI) ionisation source and operated in 
positive ion mode using the following ionisation conditions 
with a peak width of 0.7 for both Q1 and Q3: spray volt-
age 4000 V, sheath gas (nitrogen) 30 (arbitrary units), aux-
iliary gas 0 (arbitrary units), capillary temperature 375 °C 
and skimmer offset -12 V. Detection was performed in sin-
gle reaction monitoring (SRM) scan mode with the follow-
ing SRM transitions and collision energies at a collision gas 
(Argon) pressure of 1.5 mTorr: putrescine 555.2–170@31 V, 
1,7-diaminoheptane (internal standard) 597.2–170@37 V, 
N1-acetylspermidine 654.2–100@26 V, N8-acetylspermi-
dine 654.2–362@26 V, N1,N12-diacetylspermine 753.2–
100@31 V, spermidine 845.2–360@34 V, N1-acetylspermine 
944.5–100@31 V and spermine 1135.3–360@45 V. The 
resolution setting for both Q1 and Q3 was 0.2 and each SRM 
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scan time was 0.1 s. Thermo Xcalibur software (v. 2.0.7 
SP1) was used for peak integration and quantification was 
achieved by comparing the peak area ratios with those from 
calibration curves constructed from the pure standards in the 
concentration range 0.016–1.0 nmol.
Total cellular protein determination (Lowry assay)
Total cellular protein content was determined by a modi-
fied method from Lowry et al. (1951) using a 96-well 
plate. A standard linear curve was prepared in the range of 
0–250 µg/ml using 0.5 mg/ml bovine serum albumin (BSA) 
and 0.3 M NaOH. Samples were exposed to 0.13 M Folin–
Ciocalteau reagent for 20 min in the dark and absorbance 
was measured at a wavelength of 690 nm. Total cellular 
protein content was expressed as mg/culture.
Polyamine export measurement
Polyamine efflux can be measured by quantifying total [3H] 
labelled polyamines in the extracellular media after pre-
labelling cells with [3H] putrescine (Wallace and Mackarel 
1998). The cells were incubated in the addition of 18.5 kBq/
ml of [3H]-putrescine for 36 h. After replacing with fresh 
medium and further 12 h incubation, the cells were har-
vested in a time course. The medium volume was recorded 
and centrifuged. 1 ml of the medium supernatant was mixed 
with 0.25 ml of 1 M HClO4, and the cell pellet was re-sus-
pended in 1 ml of 0.2 M HClO4 for polyamine extraction. 
50 µl of the supernatant from the cell extract plus 450 µl 
of RPMI 1640 medium, and 450 µl from the [3H] medium 
extract plus 50 µl of 0.2 M HClO4 were analysed by a Can-
berra Packard 1900A liquid scintillation analyser. The total 
radioactivity [disintegrations per minute (dpm)] was the 
sum of the cell (intracellular) and the medium (extracel-
lular) fraction radioactivity. The extracellular radioactivity 
was expressed as a percentage of the total radioactivity.
Statistical method
Statistical analysis was performed using GraphPad soft-
ware Prism 5 (GraphPad Software, Inc., 2236 Avenida de 
la Playa, La Jolla, CA 92037, USA). Results were analysed 
by two-way analysis of variance (ANOVA) with Bonfer-
roni post-tests. A p value of less than 0.05 was considered 
as statistically significant. There are no ethical issues with 
this manuscript as all work was carried out on cell lines.
Results
Initial studies investigated the efficacy of the “Tet-off” 
system and determined SSAT enzyme activity in both 
SSAT− and SSAT+ cells over time. Activity in SSAT+ 
cells was about 10-18 fold higher than that in SSAT− cells 
and increased in a time-dependent manner (Fig. 1). SSAT 
activity in SSAT− cells remained low throughout (Fig. 1). 
Thereby, confirming that SSAT activity can be altered by 
using the “Tet-off” system. Western blot and qPCR con-
firmed increased protein and mRNA in the SSAT+ cells 
(results not shown). The activity in the SSAT− cells was 
lower than the equivalent wild type LNCaP cells (results 
not shown). Increased SSAT expression altered the growth 
of the cells with increased SSAT activity inhibiting 
Fig. 1  SSAT activity in induced and non-induced LNG53 cells. 
Cells were seeded at a density of 2.4 × 104/cm2 in 60 mm cell cul-
ture dish in duplicate. Cells were harvested at 24 h intervals. Media 
were replaced with fresh media at 24, 72 h. Results shown are 
mean ± SEM (n = 3, with 4 replicate per experiment). Statistical 
analysis was performed by two-way ANOVA with Bonferroni post-
test. ***p < 0.001
Fig. 2  Growth of induced (SSAT+) and non-induced (SSAT−) cells. 
Cells were seeded at a density of 2.4 × 104/cm2 in 60 mm cell culture 
dish in duplicate. Cells were harvested at 24 h intervals and viable 
cell numbers counted using Trypan blue exclusion assay. Results 
shown are mean ± SEM (n = 4–16, with 2 replicate per experiment). 
Statistical analysis was performed by two-way ANOVA using Prism 
5. ***p < 0.001
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cell growth (Fig. 2) and prolonging the generation time 
(Table 1). The activity of the main polyamine biosyn-
thetic enzyme, ornithine decarboxylase (ODC), was also 
increased dramatically in SSAT+ cells (Table 2A).
Analysis of the intracellular polyamine concentrations in 
response to altered SSAT activity showed marked increases 
in N1-acetylpolyamines and putrescine in SSAT+ cells 
(53-, 16-, and fivefold increases in N1-acetylspermidine, 
N1-acetylspermine, and putrescine respectively). Spermine 
decreased by 57 % but there was little change in spermidine 
in SSAT+ cells. Overall, there was little difference in the 
total polyamine content (Table 3). The alterations of intra-
cellular polyamine concentrations were consistent with the 
altered enzyme activity of SSAT and ODC in these cells.
Our hypothesis was that the cells with altered SSAT 
activity would respond differently to aspirin. However, 
when the apparent IC50 of aspirin, a chemopreventative 
agent, was determined by MTT assay the values were 
found to be similar (2.83 ± 0.09 and 2.64 ± 0.16 in SSAT− 
and SSAT+ respectively. 2 mM aspirin was therefore cho-
sen for the remainder of the study.
The effect of aspirin on cell growth was investigated. 
Increased SSAT activity decreased the sensitivity of the 
cells to aspirin, at least, initially. In the treated cells, the 
growth of SSAT− cells was inhibited by 25 % (24 h) and 
58 % (48 h), however, in SSAT+ cells the growth inhibi-
tion was 2 % (24 h) and 28 % (48 h), respectively (Table 4). 
This indicates that the cells with higher SSAT activity are 
resistant to aspirin treatment at an early stage. Aspirin can 
inhibit cell proliferation by depleting total intracellular pol-
yamines in vitro (Wallace and Hughes 2006). As shown in 
Table 5, total polyamines were decreased by aspirin, which 
corresponded to the results of growth inhibition. These dif-
ferences in growth inhibition were no longer obvious by 72 
and 96 h (Table 4). This is because the SSAT activity in 
SSAT+ cells was decreased (from more than 40 to less than 
10) by aspirin to a level similar to that in SSAT− cells at 72 
and 96 h. As a result, the growth inhibition between these 
two cell types was no longer different.
Aspirin at 20 µM was more potent than 100 µM as an 
inducer of SSAT activity in colon cancer cells (Babbar 
Table 1  Generation time in SSAT− and SSAT+ cells
Cells were seeded at a density of 2.4 × 104 /cm2 in 60 mm cell cul-
ture dish in duplicate. Viable cell numbers were counted using Trypan 
blue exclusion assay. Mean of the viable cell numbers were used to 
calculate generation time (Gt). Results were calculated by the equa-
tion Gt = log2 × Δt/log(N/N0) related to the total viable cell num-
bers at 24 h. Δt change in time (h), N final cell number, N0 initial cell 
number
Time of culture 48 h 72 h 96 h
Cell type Generation time (h)
SSAT− 39 34 34
SSAT+ 50 62 51
Table 2  ODC enzyme activity 
in SSAT− and SSAT+ cells
Cells were seeded at a density of 2.4 × 104 /cm2 in a 60 mm cell culture dish in duplicate. (A) The cells 
were harvested at a 24 h interval till 96 h in culture. (B) After 48 h incubation, the cells were treated with 
2 mM aspirin for 24 and 48 h. Results shown are mean ± SEM (n = 3, with 2 replicate per experiment). 
Statistical analysis was performed by 2-way ANOVA with Bonferroni post-tests using Prism 5. ** p < 0.01, 
*** p < 0.001
Time in culture (h) 24 48 72 96
(A)
 SSAT− 1.56 ± 0.38 1.58 ± 0.23 1.30 ± 0.29 1.27 ± 0.20
 SSAT+ 3.89 ± 0.47*** 5.73 ± 0.65*** 3.35 ± 0.20*** 3.48 ± 0.38***
Time of treatment (h) SSAT− SSAT+
Control Aspirin (2 mM) Control Aspirin (2 mM)
(B)
 24 0.96 ± 0.13 0.18 ± 0.08*** 2.74 ± 0.28 1.70 ± 0.25**
 48 0.63 ± 0.14 0.39 ± 0.14 1.16 ± 0.15 0.49 ± 0.10
Table 3  Polyamine 
concentrations in SSAT− and 
SSAT+ cells at 96 h in culture
Cells were seeded at a density of 2.4 × 104 /cm2 on a 60 mm cell culture dish in duplicate, media were 
replaced every 48 h. After 96 h incubation, polyamine fraction was extracted by perchloric acid and 
finally quantified by LC–MS-MS. Values are mean ± SEM with n = 6, two replicates per experiment. 
*** p < 0.001
N1-ac-spd N1-ac-spm Put Spd Spm Total
SSAT− 0.12 ± 0.03 0.03 ± 0.01 0.27 ± 0.08 3.08 ± 0.47 11.04 ± 0.82 14.54
SSAT+ 6.34 ± 0.74*** 0.50 ± 0.12*** 1.24 ± 0.14*** 2.06 ± 0.30 4.75 ± 0.66*** 14.89
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et al. 2006). This was consistent with our studies in wild 
type LNCaP prostate cancer cells where aspirin induced 
SSAT activity (around twofold but not statistically sig-
nificant) in less than 48 h (results not shown). However, 
it appeared the higher aspirin concentrations the lower its 
potency to induce SSAT activity. As aspirin modulates the 
growth of prostate cancer cells we investigated whether 
aspirin affected SSAT activity when the enzyme activity 
was altered. In SSAT− cells, the Sat1 gene expression was 
blocked by tetracycline, although treatment with aspirin 
showed a significant decrease of SSAT activity at 72 and 
96 h (Fig. 3a). The actual non-induced SSAT enzyme activ-
ity in living cells is extremely low (<5 pmol/min/mg pro-
tein), this should not indicate a biological consequence. In 
SSAT+ cells, treatment with aspirin suppressed the induced 
activity with a fivefold decrease from 24 to 96 h (Fig. 3b). 
Aspirin exposure decreased ODC activity in both SSAT+ 
and SSAT− cells (Table 2B). Overall, the results indicate 
that aspirin can act either as an inducer or an inhibitor to 
SSAT activity, and it depends on the status of cellular SSAT 
activity.
Changes in both ODC and SSAT activities as a result of 
treatment with aspirin led to alterations in the intracellular 
concentrations of polyamines. Treatment with aspirin had 
little effect overall on the intracellular polyamine content 
of SSAT− cells (Fig. 4a–e). In the SSAT+ cells, however, 
N1-acetylspermidine and putrescine decreased significantly 
and N1-acetylspermine showed a tendency to decrease 
(Fig. 4a–e). As N1-acetylspermidine and putrescine are the 
major polyamines exported from cells when cell growth is 
inhibited (Wallace et al. 2003) we investigated the effect 
of aspirin exposure on polyamine export. On the other 
hand, accumulation of N1-acetylspermidine and putrescine 
Table 4  Effect of aspirin on the growth inhibition of SSAT− and 
SSAT+ cells
Cells were seeded at a density of 2.4 × 104 /cm2 in a 60 mm cell 
culture dish in duplicate. Cells were treated with aspirin after 48 h 
incubation and then harvested at 24 h intervals and viable cell num-
bers counted using Trypan blue exclusion assay. Growth inhibition 
(%) was calculated as a percentage of the number of cells treated with 
aspirin against the number of cells of control. The growth inhibition 
of control cells was known as 0 % (n = 3–8, with two replicates per 
experiment)
Cells Growth inhibition (%)
Time of treatment (h) 24 48 72 96
SSAT− 25 58 80 81
SSAT+ 2 28 73 83
Table 5  Effect of aspirin on total polyamine concentrations
Cells were seeded at a density of 2.4 × 104 /cm2 on a 60 mm cell 
culture dish in duplicate. Media were replaced after the initial 24 h 
growth and then at a 48 h interval. Cells were treated with aspirin 
(2 mM) after 48 h incubation and harvested at a 24 h interval; poly-
amine fraction was extracted by perchloric acid and finally quanti-
fied by LC–MS. Statistical analysis was performed using Two-way 
ANOVA with Bonferroni post-tests comparing with Control. p > 0.05
Time of treatment 
(h)
Total Polyamines (nmol/mg protein)
24 48 72 96
SSAT−
 Control 17.1 ± 3.0 21.5 ± 3.8 12.6 ± 3.3 12.1 ± 3.3
 Aspirin 14.9 ± 4.5 8.9 ± 1.3 8.1 ± 1.5 8.4 ± 2.1
SSAT+
 Control 24.0 ± 6.6 34.8 ± 8.5 17.8 ± 5.0 11.1 ± 2.2
 Aspirin 17.0 ± 3.8 10.7 ± 2.4 6.8 ± 1.8 7.1 ± 2.2
Fig. 3  Effect of aspirin on the SSAT enzyme activity. Cells were 
seeded at a density of 2.4 × 104/cm2 on a 60 mm tissue culture dish 
in duplicate. After 48 h cell growth, the medium was replaced with 
fresh medium containing aspirin (2 mM). SSAT activity was assayed 
after 48 h drug exposure. a Effect of aspirin on SSAT activity in 
SSAT− cells. b Effect of aspirin on SSAT activity in SSAT+ cells. 
Values were mean ± SEM (n = 3 with 4 replicates per experiment). 
Statistical analysis was performed using two-way ANOVA with Bon-
ferroni post-tests. *p < 0.05, **p < 0.01, ***p < 0.001
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could render the cells resistant to aspirin within 48 h before 
majority of them were exported out of the cells.
Polyamine efflux was increased significantly in SSAT+ 
in a time dependent manner in contrast to SSAT− cells, 
indicating that polyamine export or efflux was augmented 
by SSAT overexpression (Fig. 5). This was not affected by 
aspirin treatment but aspirin did increase export in SSAT− 
cells at 48 h.
Fig. 4  Effect of aspirin on polyamine content in SSAT− and SSAT+ 
cells. Cells were seeded at a density of 2.4 × 104/cm2 on a 60 mm 
cell culture dish in duplicate. Media were replaced after the initial 
24 h growth and then at a 48 h interval. Cells were treated with aspi-
rin (2 mM) after 48 h incubation and harvested at a 24 h interval; 
polyamine fraction was extracted by perchloric acid and finally quan-
tified by LC–MS-MS. a N1-acetylspermidine; b N1-acetylspermine; 
c Putrescine; d Spermidine; e Spermine; f Total polyamines. Values 
are mean ± SEM with n = 3–6, two duplicates per experiment). Sta-
tistical analysis was performed using Two-way ANOVA with Bon-
ferroni post-tests comparing with Control. *p < 0.05; **p < 0.01; 
***p < 0.001
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Discussion
Aspirin has been shown to be a chemopreventative agent in 
colorectal cancer (Thun et al. 2012) and may be useful in 
preventing other cancers. One mechanism by which aspirin 
can prevent colorectal cancer development is through inhi-
bition of COX-2 enzyme (Sostres et al. 2014). However, 
additional COX-independent pathways have been discov-
ered in a number of other studies (Chan et al. 2007; Hubner 
et al. 2008; Babbar et al. 2006). In our laboratory, NSAIDs 
such as naproxen have been shown to induce SSAT and 
cause cytotoxicity in HCT-115 colorectal cancer cells with 
no COX activity. This indicates a link between SSAT activ-
ity and inhibition of cancer cell growth, i.e. SSAT induction 
leading to depletion of intracellular polyamine pools and 
decreased cell growth (Hughes et al. 2012). Similarly, aspi-
rin induced SSAT activity in Caco-2 cells that ultimately 
led to a decrease in cellular polyamine content. Thus, acti-
vation of SSAT by aspirin may play a role in chemopre-
vention in colon carcinogenesis by decreasing the content 
of polyamine growth factors (Babbar et al. 2006). In this 
study, overexpression of SSAT appeared to result in a rise 
in total polyamine content instead of polyamine depletion 
in SSAT+ cells. This was consistent with the study by Kee 
Fig. 4  continued
Fig. 5  Effect of aspirin on polyamine export. Cells were seeded at 
a density of 2.4 × 104/cm2 in a 60 mm cell culture dish in duplicate 
and incubated for 24 h. The cells were then incubated with [3H]-
putrescine for 36 h. After removal of the [3H]-putrescine for 12 h, 
the cells were dosed with the drug(s) and harvested at 0, 6, 12, 24 
and 48 h. Radioactivity was quantified using liquid scintillation ana-
lyser. Results shown are mean ± SEM (n = 3, with two replicates per 
experiment). Statistical analysis was performed by two-way ANOVA 
with Bonferroni post-tests using Prism5. Polyamine export was sig-
nificantly higher in SSAT+ than SSAT− cells without treatment. Aspi-
rin only increased the polyamine export in SSAT− cells at 48 h treat-
ment. ***p < 0.001, ƗƗƗp < 0.001
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et al. (2004). These results suggest that depletion of intra-
cellular polyamine pools by SSAT induction can be cell 
type dependent.
There is a lack of clinical evidence that aspirin can pre-
vent prostate cancer development although some studies 
indicate that there is an inverse association of aspirin use 
and the development of prostate cancer (Nelson and Harris 
2000). In the present study, induced SSAT activity not only 
inhibited the cell proliferation but desensitised the cells to 
aspirin. Thus, it provides in vitro evidence that sensitivity 
of human prostate cancer cells to NSAIDs (aspirin) is asso-
ciated with the status of cellular SSAT activity.
SSAT overexpression was not only growth inhibi-
tory, but also resulted in resistance to aspirin. A shift from 
resistance to sensitivity of the cells was simultaneously 
concomitant with a decrease of induced SSAT activity in 
response to aspirin. To our knowledge, this is the first time 
that SSAT activity was found to be associated with aspi-
rin resistance or sensitivity in human tumour cells in vitro. 
Thus, the efficacy of aspirin in cancer prevention is likely 
to be associated with inherent cellular SSAT activity. SSAT 
mRNA was found increased in cancerous human prostate 
specimens compared with their benign counterparts. In 
addition, increased SSAT mRNA was more observed in 
Gleason score 8 than score 2 in these specimens (Bettuzzi 
et al. 2000). Thereby, cancer cells with high natural SSAT 
activity might be expected to be more resistant to NSAIDs 
than cells with low SSAT activity. Our results indicate that 
the cell resistance to aspirin may occur at an early stage 
in the treatment and it would reduce with time until SSAT 
activity is lowered to normal level.
Aspirin tends to induce to SSAT gene expression and 
activity only if cellular SSAT activity is at normal or low 
level. When SSAT activity is pre-induced, aspirin, espe-
cially at a higher concentration (2 mM), inhibits the SSAT 
activity. This suggests that whether aspirin is an inducer or 
inhibitor of SSAT, depends on status of cellular SSAT.
The SSAT reduction by aspirin causing growth inhi-
bition must lead to alterations of intracellular polyamine 
concentrations since SSAT is a key regulator in polyam-
ine metabolism. As a result of considerable accumulation 
of intracellular N1-acetylpolyamines, mainly N1-acetyl-
spermidine and putrescine, the total polyamine content in 
SSAT+ cells tend to rise. It is thought that the accumula-
tion of these polyamines not only inhibits the cell growth 
but also renders aspirin resistance the cells. A typical phe-
notype (hair loss and wrinkled skin) of SSAT transgenic 
mice is believed to be due to the massive accumulation 
of putrescine in the skin (Pietilä et al. 1997), thus putres-
cine accumulation may be toxic. On the other hand, low 
concentrations of spermidine and spermine may also pre-
vent the cells from proliferating and differentiating, since 
spermidine and spermine are known to be involved in both 
processes. Our results further confirmed the speculation 
that either an accumulation or a depletion of intracellular 
polyamines could be detrimental to the cell. Furthermore, 
polyamine export is an important part of the regulation of 
intracellular polyamine concentrations, and this process 
is also closely associated with SSAT activity. Thereby, 
the slow proliferation rate of SSAT+ cells is likely to be 
linked to the altered balance in the intracellular polyamine 
content.
The polyamine metabolic pathway has been recognised 
as a target for cancer therapy and alternations in polyam-
ine content affect cell proliferation. Based on our findings, 
aspirin is expected to lower SSAT activity in early prostate 
tumours, therefore enhancing the sensitivity of the tumour 
cells to the drug and finally preventing tumour development 
via changing cellular polyamine content. We demonstrated 
that SSAT acts as a determinant on the chemopreventative 
effect of aspirin in prostate tumour cells. This determina-
tion is closely associated with concentrations of each of the 
intracellular polyamines.
In summary, the present study suggests that the mecha-
nisms by which aspirin prevents the growth of cancer cells 
may involve polyamine metabolism as was found in colon 
cancer cells and may be independent of COX pathways. 
Modification of intracellular polyamine concentrations 
via changes in SSAT activity is associated with the rate of 
prostate cancer cell proliferation but also with the sensitiv-
ity of the cells to aspirin. This is the first time this link has 
been shown. In the use of aspirin to prevent the growth of 
prostate cancer cells, intracellular polyamine content may 
play an important role in determining the sensitivity of the 
cells and SSAT may be a both a target for aspirin and a key 
regulator of drug response.
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